**Abstract**

**Objective:** In this study, we evaluated the changes of peripheral immune-inflammatory markers relevant to the clinical course in patients with bipolar disorder to look into the possibility of immune-inflammatory markers as a potential biomarker for staging bipolar disorder(BD).

**Method:** Patients with BD and healthy controls were compared to see the abnormalities in peripheral immune-inflammatory markers using TNF-alpha, IL-6, mcp1/ccl2, CRP, BDNF, and Vitamin D. We also evaluated the changes of peripheral immune-inflammatory markers episodically in response to the clinical course and mood states e.g. acute, continuation and maintenance phase.

**Results:** A total of 17 patients with bipolar mania(60%female; mean age 46.8±10.6 years; mean duration of illness 16.2±10.6 years; mean YMRS scores 43.4±4.5; mean MADRS scores 1.8±3.0) and 40 healthy controls (52.6%female; mean age 38.7±14.1years) were enrolled. There were no statistically significant differences between the two groups for sex and age. IL-6 and CRP were consistently increased in BD compared with control group.

The result for IL-6 showed that the mean difference is 2.64±0.80 pg/mL(p=0.002) in acute phase and 1.38±0.56 pg/mL(p=0.018) in maintenance phase. The result for CRP showed that the mean difference is 4.95±1.42 mg/L(p=0.001) in acute phase and 1.33±0.59 mg/L(p=0.028) in maintenance phase. MCP1/CCL2 was changed episodically in response to the clinical course and mood states (359.7±82.3 pg/mL in acute phase, 243.6±66.9 pg/mL in continuation phase, 299.4±81.5 pg/mL in maintenance phase, p=0.002).

**Conclusion:** Our results suggest that immune-inflammatory activity is possible to be correlated with the episodic clinical course of BD. Larger samples of BD should be studied for further investigation.
